Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.

Blokx WA, Lesterhuis WJ, Andriessen MP, Verdijk MA, Punt CJ, Ligtenberg MJ.

Am J Surg Pathol. 2007 Apr;31(4):637-41. Erratum in: Am J Surg Pathol. 2007 Jul;31(7):1137. Lesterhuis, Joost J [corrected to Lesterhuis, W Joost]; Punt, Kees J A [corrected to Punt, Cornelis J A].

PMID:
17414113
2.

Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.

Küsters-Vandevelde HV, Keunen JE, Wesseling P, Verdijk MA, Ligtenberg MJ, Blokx WA.

Virchows Arch. 2008 Mar;452(3):331-6. doi: 10.1007/s00428-007-0555-8.

PMID:
18205010
3.

Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.

Nagore E, Montoro A, García-Casado Z, Botella-Estrada R, Insa A, Lluch A, López-Guerrero JA, Guillén C.

Melanoma Res. 2009 Aug;19(4):211-4. doi: 10.1097/CMR.0b013e3283281057.

PMID:
19571771
4.

CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.

Rutter JL, Goldstein AM, Dávila MR, Tucker MA, Struewing JP.

Oncogene. 2003 Jul 10;22(28):4444-8.

PMID:
12853981
5.

CDKN2A mutation and deletion status in thin and thick primary melanoma.

Cachia AR, Indsto JO, McLaren KM, Mann GJ, Arends MJ.

Clin Cancer Res. 2000 Sep;6(9):3511-5.

6.

Role of the CDKN2A locus in patients with multiple primary melanomas.

Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzàlez U, Castel T, Campoy A, Herrero J, Martí R, Brunet-Vidal J, Milà M.

J Clin Oncol. 2005 May 1;23(13):3043-51.

7.

The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma.

Huber J, Ramos ES.

Braz J Med Biol Res. 2006 Feb;39(2):237-41. Epub 2006 Feb 2.

8.

Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.

Berg P, Wennberg AM, Tuominen R, Sander B, Rozell BL, Platz A, Hansson J.

Melanoma Res. 2004 Aug;14(4):251-5.

PMID:
15305154
9.
10.

Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation.

Edinger JT, Radfar A, Jukic DM.

J Cutan Pathol. 2009 Oct;36 Suppl 1:74-9. doi: 10.1111/j.1600-0560.2008.01226.x. Epub 2009 Mar 5.

PMID:
19281486
11.

Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.

Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group.

J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15.

12.

Simultaneous occurrence of primary choroidal and cutaneous malignant melanoma and skin metastasis.

Eide N, Foerster A.

Acta Ophthalmol (Copenh). 1993 Aug;71(4):496-9.

PMID:
8249581
13.
14.

Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families.

Måsbäck A, Olsson H, Westerdahl J, Sandberg T, Borg A, Jonsson N, Ingvar C.

Melanoma Res. 2002 Dec;12(6):549-57.

PMID:
12459644
15.

Morphologic diversity in malignant melanoma: the potential use of microdissection and the polymerase chain reaction for diagnosis.

Quezado MM, Abati AD, Albuquerque AV, Wilson J, Merino MJ, Filie AC.

Mod Pathol. 1998 Oct;11(10):1010-5.

PMID:
9796732
16.

Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.

Levanat S, Situm M, Crnić I, Marasović D, Puizina-Ivić N, Pokupcić N, Musani V, Komar A, Kubat M, Furac I, Karija-Vlahović M, Krizanac S.

Croat Med J. 2003 Aug;44(4):418-24.

17.

CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.

Lang J, Boxer M, MacKie RM.

Br J Dermatol. 2005 Dec;153(6):1121-5.

PMID:
16307646
18.

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE.

Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63. Erratum in: Genes Chromosomes Cancer. 2007 Jul;46(7):716.

PMID:
17001621
19.

BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, Guinebretière JM, Marian C, Barrois M, Boitier F, Lenoir GM, Bressac-de Paillerets B.

Fam Cancer. 2007;6(4):453-61. Epub 2007 Jul 12.

PMID:
17624602
20.

Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.

Mantelli M, Pastorino L, Ghiorzo P, Barile M, Bruno W, Gargiulo S, Sormani MP, Gliori S, Vecchio S, Ciotti P, Sertoli MR, Queirolo P, Goldstein AM, Bianchi-Scarrà G; Italian Melanoma Intergroup.

Melanoma Res. 2004 Dec;14(6):443-8.

PMID:
15577313
Items per page

Supplemental Content

Write to the Help Desk